Disease Definition, Nomenclature, and Regulatory Endpoints
The field is undergoing a critical nomenclature transition. Metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) with its inflammatory subtype MASH (metabolic dysfunction-associated steatohepatitis) have replaced the older NAFLD/NASH terminology to emphasize metabolic drivers rather than alcohol exclusion25. However, clinical overlap is substantial: 97.3% of NAFLD cases meet MASLD criteria18, and >99% of biopsy-confirmed MASH patients in the pivotal ESSENCE trial met cardiometabolic criteria despite this not being an enrollment requirement1.
Diagnostic and Staging Criteria
The FDA's 2018 guidance established regulatory standards that remain foundational3. Inclusion criteria for trials require histological diagnosis within 6 months showing NAFLD activity score (NAS) ≥4 with ≥1 point each in inflammation and ballooning, plus fibrosis stage F2 or F3 (NASH Clinical Research Network scale). Accelerated approval pathways accept three histological endpoints as reasonably likely surrogates: (1) NASH resolution (NAS 0-1 for inflammation, 0 for ballooning) without fibrosis worsening; (2) fibrosis improvement ≥1 stage without NASH worsening; or (3) both3. Confirmatory trials must demonstrate clinical benefit: progression to cirrhosis, hepatic decompensation, Model for End-Stage Liver Disease (MELD) score increase from ≤12 to >15, transplantation, or mortality3.
Noninvasive tests (NITs) for screening and monitoring show heterogeneous performance. FIB-4 is recommended as first-line screening, but 34.5% of ESSENCE participants with biopsy-confirmed F2-F3 fibrosis had FIB-4 <1.3 (false negatives)17. Magnetic resonance elastography (MRE) is superior to vibration-controlled transient elastography (VCTE) and FIB-4 for detecting significant fibrosis (≥F2), with area under the receiver operating characteristic curve (AUROC) 0.848 vs. 0.632 and 0.664, respectively12. However, inflammation confounds elastography: when aspartate aminotransferase (AST) ≥2× upper limit of normal or inflammation grade ≥2, liver stiffness measurement overestimates fibrosis in F1-F2 stages20. MRI proton density fat fraction (PDFF) quantifies steatosis with repeatability coefficients of 1.2-1.6%19 but does not correlate with fibrosis and exhibits large placebo effects21.
Lifestyle and Metabolic Interventions
Weight loss thresholds are evidence-based and quantitative2: 3-5% weight loss reduces steatosis; 7% induces MASH resolution; 10% achieves fibrosis regression. Mediterranean-style diet, Dietary Approaches to Stop Hypertension (DASH), and low-carbohydrate diets all demonstrate metabolic and hepatic benefits2. Caloric restriction of 500-1,000 kcal/day improves insulin resistance and liver fat. Resistance exercise is particularly suitable for patients with contraindications to aerobic activity2.
Bariatric Surgery
Current guidelines recommend metabolic surgery for non-cirrhotic MASLD patients meeting weight loss surgery criteria. Systematic reviews demonstrate acceptable perioperative and long-term safety in compensated cirrhosis with portal hypertension, though postoperative alcoholic cirrhosis risk may increase2. Endoscopic sleeve gastrectomy (ESG) has emerged as a less invasive alternative, though robust comparative evidence is still required3536. The treatment paradigm is shifting from lifestyle-based interventions toward procedural approaches, recognizing that lifestyle modifications alone are often insufficient23.
A 2023 study of pemafibrate (PPAR alpha agonist) combined with mild low-carbohydrate diet demonstrated phenotype-specific mechanisms: in obese patients (BMI ≥25 kg/m²), improvements in alanine transaminase (ALT) and MRI-PDFF correlated significantly with weight loss (r=0.659 and r=0.784, p<0.001), whereas in non-obese patients (BMI <25 kg/m²), benefits occurred independently of weight loss6. This highlights the heterogeneity of lean vs. obese MAFLD phenotypes17.
Pharmacologic Therapies: Mechanisms, Efficacy, and Safety
The pharmacologic pipeline encompasses over 42 Phase II/III trials21 targeting diverse mechanisms:
Incretin-Based Therapies
GLP-1 Receptor Agonists: Semaglutide 2.4 mg demonstrated the strongest efficacy signals in the Phase III ESSENCE trial (Part 1, n=800): 62.9% achieved NASH resolution without fibrosis worsening vs. 34.1% placebo, and 37% achieved fibrosis improvement ≥1 stage vs. 22.5% placebo21. Phase II data showed 59% NASH resolution vs. 17% placebo (p<0.001)2. However, fibrosis improvement lags NASH resolution, likely reflecting absence of direct intrahepatic anti-inflammatory/anti-fibrogenic effects2.
Dual/Triple Agonists: Network meta-analysis using surface under the cumulative ranking curve (SUCRA) methodology ranked pharmacological efficacy for MASH resolution2628:
- Pegozafermin (FGF21 analog): SUCRA 91.75
- Survodutide (dual GLP-1/glucagon): SUCRA 90.87
- Tirzepatide (dual GIP/GLP-1): SUCRA 84.70; Phase 2 showed 46-62% MASH resolution2427
Thyroid Hormone Receptor-β Agonists
Resmetirom (Rezdiffra) received FDA accelerated approval in March 20242, the first MASH-specific therapy. Phase III MAESTRO-NASH trial (n=1,759) showed 25.9-29.9% NASH resolution and 24.2-25.9% fibrosis improvement (both p<0.001 vs. placebo)21. MAESTRO-NAFLD-1 (n=1,343) demonstrated 51% achieved ≥25% liver stiffness improvement21. The mechanism enhances hepatic lipid oxidation and export without direct anti-fibrotic effects2.
PPAR Agonists
Lanifibranor (pan-PPAR alpha/delta/gamma) is in Phase III NATiV3 trial with enrollment completed April 2025 and topline results expected H2 20262231. Phase IIb NATiV showed 55% SAF-A reduction ≥2 points (1200 mg) and 31% dual endpoint response in F2/F321. This contrasts with elafibranor (PPAR alpha/delta), which failed Phase III RESOLVE-IT: 19.2% vs. 14.7% NASH resolution (p=0.066, not significant)21.
Saroglitazar (PPAR alpha/gamma) showed -45.8% ALT reduction in Phase II, with 51.8% achieving ≥50% ALT reduction vs. 3.5% placebo2132.
Lipid/Energy Pathway Targets
Denifanstat (FASN inhibitor) blocking de novo lipogenesis demonstrated in Phase IIb FASCINATE-2 (n=168): 38% achieved ≥2-point NAS improvement without fibrosis worsening vs. 16% placebo (p=0.0035); 26% achieved MASH resolution vs. 11% placebo (p=0.0173)1521. Common adverse events included alopecia (19% vs. 4% placebo) and dry eye (9% vs. 14%), all Grade 1-215. A Phase I combination study with resmetirom is underway (H1 2026)22.
Aramchol (SCD1 inhibitor) showed 31% fibrosis improvement and 26.5% NASH resolution in Phase III ARCON (open-label, n=51)21.
Anti-Inflammatory/Anti-Fibrotic Agents
FXR Agonists: Obeticholic acid (OCA) in Phase III REGENERATE (n=2,480, F2-F3) achieved 22.4% fibrosis improvement vs. 9.6% placebo (p<0.0001), but showed only 11.9% vs. 9.9% improvement in compensated cirrhosis (REVERSE trial, not significant)21. Dose-dependent pruritus (24-57%) limits tolerability21. Newer FXR agonists like FXR 314 show reduced pruritus rates (2.8-4.2%)21.
ASK1 Inhibitor (Selonsertib) failed in two Phase III trials (STELLAR-3 F3: 9.3-12.1% vs. 13.2% placebo; STELLAR-4 F4: 14.4% vs. 12.8%)21, highlighting the challenge of translating preclinical anti-fibrotic mechanisms to human efficacy.
CCR2/5 Antagonist (Cenicriviroc): Phase III AURORA was suspended for lack of efficacy despite positive Phase IIb CENTAUR showing 20% vs. 10% fibrosis improvement at Year 121.
Translational Science and Biomarker Development
Three-dimensional MRE combined with PDFF can simultaneously characterize fat content (PDFF; rho=0.853 with steatosis grade), disease activity (damping ratio; rho=0.678 with MAS grade), and fibrosis (shear stiffness; rho=0.837 with fibrosis stage)8. A three-parameter model (PDFF + shear stiffness + damping ratio) showed AUROC 0.973 for detecting Fibro-MASH (≥F2), with net reclassification improvement of 0.28 over two-parameter models8.
Genetic variants in PNPLA3, TM6SF2, and GCKR are well-established contributors driving hepatic steatosis, lipid export defects, and glucose/lipid metabolism4. Epigenetic mechanisms—DNA methylation, histone modifications, non-coding RNA regulation—also influence disease progression independent of genetic sequence4. However, translation to predictive biomarkers for treatment response remains incomplete.
5. Unresolved Scientific and Clinical Questions
Critical Knowledge Gaps Limiting Translation
| Unresolved Question | Why It Matters | Evidence Gap |
|---|---|---|
| 1. Do histological surrogates predict long-term clinical outcomes? | All approvals are accelerated based on NASH resolution/fibrosis improvement; no Phase III trial has demonstrated clinical benefit (cirrhosis prevention, decompensation, mortality)21 | Confirmatory outcomes trials (e.g., ESSENCE Part 2 240-week cirrhosis-free survival) ongoing but results unavailable until 2027-20281 |
| 2. What mechanisms drive fibrosis reversal in humans? | ASK1 and caspase inhibition failed despite strong preclinical rationale21; limits rational drug design | Disconnect between preclinical models and human biology; lack of validated anti-fibrotic targets21 |
| 3. Can any intervention reverse established cirrhosis (F4)? | Largest unmet need; OCA and emricasan failed in cirrhosis21 | Only resmetirom shows preliminary signals in cirrhosis (51% liver stiffness improvement)21; most trials exclude F4 |
| 4. Do lean, obese, diabetic, and pediatric MASH require different therapies? | Pemafibrate-LCD study suggests differential mechanisms by BMI6; pediatric cysteamine trial failed21 | Phenotype-specific trials lacking; one-size-fits-all designs may dilute efficacy in responsive subgroups1721 |
| 5. What is the optimal combination therapy strategy? | Metabolic agents show NASH resolution but modest fibrosis improvement; anti-fibrotic agents show inverse pattern21 | Only one combination trial (cilofexor/firsocostat) reported, did not meet primary endpoint21; denifanstat+resmetirom in Phase I22 |
| 6. How can noninvasive tests distinguish fibrosis from inflammation? | MRE overestimates fibrosis when AST ≥2× ULN or inflammation grade ≥220 | No validated biomarker corrects for inflammation confounding; limits trial enrichment and monitoring1120 |
| 7. What are 5-10 year cardiovascular and metabolic safety profiles? | Longest trials are 52-72 weeks21; chronic treatment safety unknown | No long-term safety data; regulatory and payer hesitancy for indefinite therapy21 |
| 8. Can trial efficacy translate to real-world heterogeneous populations? | No pragmatic trials or real-world evidence studies21 | Efruxifermin SYNCHRONY Real-World Phase III (H1 2026) is first RWE trial2233 |
| 9. Which biomarkers can replace liver biopsy for diagnosis and monitoring? | Biopsy is invasive with sampling error; NITs show heterogeneous performance1712 | No single biomarker qualified by regulators; combinations (e.g., 3D-MRE + PDFF) promising but require validation811 |
| 10. What are causal drivers of progression from steatosis to MASH to cirrhosis? | Only ~20% of steatosis progresses to MASH; progression heterogeneity unexplained | Longitudinal natural history studies with deep phenotyping lacking9 |
| 11. How does dynamic disease classification affect trial design? | Patients transition between MASLD/MASH categories over time9 | Static baseline classification doesn't capture phenotypic fluidity; adaptive trial designs needed9 |
| 12. What is the interaction between alcohol, viral hepatitis, medications, and MASLD? | MetALD (metabolic and alcohol-related) represents 7.9% of steatotic liver disease with distinct phenotype1618 | Exclusion from MASLD definition limits understanding of additive/synergistic effects |
Forward-Looking Catalysts (2026-2027)
Five major readouts are anticipated in the next 12-24 months22:
H1 2026:
- Efruxifermin (FGF21 analog) SYNCHRONY Real-World Phase III: First real-world evidence component in MASH trials; validates pragmatic effectiveness and adherence2231
- Denifanstat + Resmetirom Phase I Combination Study: First metabolic+metabolic combination PK data; enables Phase II initiation if no drug-drug interaction22
H2 2026:
- Lanifibranor (pan-PPAR) NATiV3 Phase III: Enrollment completed April 2025; first pan-PPAR readout may validate broader activation vs. selective agonism2231
2026-2027:
- Pemvidutide (dual GLP-1/glucagon) IMPACT Phase IIb Final Results: FDA Fast Track designation for alcohol use disorder August 2025; dual agonism may offer superior weight loss22
H1 2027:
- Efruxifermin SYNCHRONY Histology Phase III: Confirmatory histological endpoint trial; if positive, positions for full FDA approval2231
Additional catalysts not captured in the limited dataset include semaglutide ESSENCE Part 2 clinical outcomes (2027-2028), resmetirom MAESTRO-NASH-OUTCOMES cirrhosis trial, and pegozafermin Phase III initiation2231.
Conclusion
The MAFLD/MASH therapeutic landscape demonstrates mechanistic diversity with variable clinical translation. Metabolic modulators (GLP-1 RAs, THR-β agonists) achieve high NASH resolution rates (59-69%) but modest fibrosis improvement; FXR agonists show anti-fibrotic effects but face tolerability challenges; ASK1/caspase inhibition failed despite preclinical promise21. The most important unresolved questions—validation of histological surrogates for clinical benefit, fibrosis reversal biology, cirrhosis treatment, phenotypic heterogeneity, and biomarker qualification—limit regulatory approval certainty and guideline adoption2134. The field requires longer-duration trials with clinical outcomes, combination therapy optimization, and precision medicine approaches addressing the heterogeneity that currently constrains therapeutic success2125.